{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:07:52Z","timestamp":1792652872156,"version":"4.5.0"},"reference-count":42,"publisher":"AOSIS","issue":"1","license":[{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Afr. j. prim. health care fam. med."],"abstract":"<jats:p>Background: The coronavirus disease 2019 (COVID-19) has highlighted the scope of heroin dependence and need for evidence-based treatment amongst marginalised people in South Africa. Acute opioid withdrawal management without maintenance therapy carries risks of increased morbidity and mortality. Due to the high costs of methadone, Tshwane\u2019s Community Oriented Substance Use Programme (COSUP) used tramadol for opioid withdrawal management during the initial COVID-19 response.Aim: To describe demographics, route of heroin administration and medication-related experiences amongst people accessing tramadol for treatment of opioid withdrawal.Setting: Three community-based COSUP sites in Mamelodi (Tshwane, South Africa).Methods: A retrospective cross-sectional study was conducted. Data were collected using an interviewer-administered paper-based tool between April and August 2020. Descriptive statistics were used to analyse data.Results: Of the 220 service users initiated onto tramadol, almost half (n = 104, 47%) were not contactable. Fifty-eight (26%) people participated, amongst whom most were male (n = 55, 95%). Participants\u2019 median age was 32 years. Most participants injected heroin (n = 36, 62.1%). Most participants experienced at least one side effect (n = 47, 81%) with 37 (64%) experiencing two or more side effects from tramadol. Insomnia occurred most frequently (n = 26, 45%). One person without a history of seizures experienced a seizure. Opioid withdrawal symptoms were experienced by 54 participants (93%) whilst taking tramadol. Over half (n = 38, 66%) reported using less heroin whilst on tramadol.Conclusion: Tramadol reduced heroin use but was associated with withdrawal symptoms and unfavourable side effects. Findings point to the limitations of tramadol as opioid withdrawal management to retain people in care and the importance of access to first-line opioid agonists.Contribution: This research contributes to the limited data around short-acting tramadol for opioid withdrawal management in the African context, with specific focus on the need for increased access to opioid agonists for those who need them, in primary care settings.<\/jats:p>","DOI":"10.4102\/phcfm.v14i1.3386","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T09:36:08Z","timestamp":1663752968000},"source":"Crossref","is-referenced-by-count":11,"title":["Managing acute opioid withdrawal with tramadol during COVID-19 lockdown in a peri-urban setting"],"prefix":"10.4102","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2103-9858","authenticated-orcid":false,"given":"Urvisha","family":"Bhoora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2533-9540","authenticated-orcid":false,"given":"Natasha R.","family":"Gloeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3238-0699","authenticated-orcid":false,"given":"Andrew","family":"Scheibe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2580","published-online":{"date-parts":[[2022,9,28]]},"reference":[{"key":"ref0001","author":"World Health Organization","journal-title":"Opioid overdose [homepage on the Internet]"},{"key":"ref0002","year":"No date","journal-title":"United Nations World Drug Report 2020 [homepage on the Internet]"},{"key":"ref0003","author":"The Joint United Nations Programme on HIV\/AIDS (UNAIDS)","year":"2021","journal-title":"Global AIDS strategy 2021\u20132026. End inequalities. End AIDS"},{"key":"ref0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102839"},{"key":"ref0005","author":"Scheibe","year":"2020","journal-title":"Insights into the market value of heroin, cocaine and methamphetamine in South Africa"},{"key":"ref0006","author":"World Health Organization","year":"2009","journal-title":"Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence"},{"key":"ref0007","author":"United Nations Office on Drugs and Crime (UNODC), International Network of People who Use Drugs (INPUD), The Joint United Nations Programme on HIV\/AIDS (UNAIDS)","year":"2017","journal-title":"Implementing comprehensive HIV and HCV programmes with people who inject drugs. Practical guidance for collaborative interventions. (IDUIT)"},{"key":"ref0008","author":"Global Initiative Against Transnational Organised Crime","year":"2020","journal-title":"South African drug market survey"},{"key":"ref0009","author":"National Department of Health","year":"2019","journal-title":"Standard treatment guidelines and essential medicines list for South Africa [homepage on the Internet]"},{"key":"ref0010","doi-asserted-by":"publisher","DOI":"10.7196\/SAMJ.2018.v108i10.13397"},{"key":"ref0011","doi-asserted-by":"publisher","DOI":"10.11604\/pamj.2021.38.84.21991"},{"key":"ref0012","author":"Health-E News","year":"No date","journal-title":"Medicine price registry [homepage on the Internet]"},{"key":"ref0013","volume":"23","author":"South African Community Epidemiology Network on Drug Use","year":"2021","journal-title":"SACENDU research brief phase 48"},{"key":"ref0014","author":"Austell Laboratories (Pty) Ltd","year":"2007","journal-title":"Austell Tramadol [package insert]"},{"issue":"7","key":"ref0015","first-page":"e9128","volume":"12","author":"Shah","year":"2020","journal-title":"Cureus"},{"key":"ref0016","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.1838"},{"key":"ref0017","doi-asserted-by":"publisher","DOI":"10.1080\/10550490500528712"},{"key":"ref0018","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2012.665728"},{"key":"ref0019","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-007-0847-3"},{"issue":"1","key":"ref0020","first-page":"49","volume":"14","author":"Khine","year":"2015","journal-title":"Afr J Drug Alcohol Stud"},{"key":"ref0021","author":"University of California San Francisco, Anova Health Institute, National Institute for Communicable Diseases","year":"2018","journal-title":"Brief report of the TipVal study: An integrated bio-behavioral surveillance survey among people who inject drugs"},{"key":"ref0022","author":"Dada","year":"2021","journal-title":"January-June 2020 | Phase 48: Monitoring alcohol, tobacco and other drug abuse treatment admissions in South Africa"},{"key":"ref0023","author":"Dada","year":"2021","journal-title":"July\u2013December 2020 | Phase 49: Monitoring alcohol, tobacco and other drug abuse treatment admissions in South Africa"},{"key":"ref0024","doi-asserted-by":"publisher","DOI":"10.4102\/phcfm.v12i1.2285"},{"key":"ref0025","author":"Community Oriented Substance Use Programme","year":"2020","journal-title":"Key performance indicators: Monthly report to the City of Tshwane"},{"key":"ref0026","author":"Republic of South Africa","year":"No date","journal-title":"About alert system [homepage on the Internet]"},{"key":"ref0027","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-020-00404-0"},{"issue":"1","key":"ref0028","first-page":"17","volume":"2021","author":"Scheibe","year":"2021","journal-title":"S Afr Health Rev"},{"key":"ref0029","author":"World Health Organization","year":"2020","journal-title":"The alcohol, smoking and substance involvement screening test (ASSIST). Manual for use in primary care"},{"key":"ref0030","author":"Republic of South Africa","year":"No date","journal-title":"Statistics South Africa. Statistics by place [homepage on the Internet]"},{"key":"ref0031","author":"Leximcorp","year":"2021","journal-title":"Tramadol: Drug information"},{"key":"ref0032","author":"US Department of Health and Human Services","journal-title":"Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events [homepage on the Internet]"},{"key":"ref0033","doi-asserted-by":"publisher","DOI":"10.1177\/0269094217727990"},{"key":"ref0034","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108302"},{"key":"ref0035","doi-asserted-by":"publisher","DOI":"10.7196\/SAMJ.2020.v111i1.14884"},{"key":"ref0036","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-019-1256-2"},{"key":"ref0037","first-page":"274","volume":"12","author":"Scheibe","year":"2020","journal-title":"Rev Int Polit D\u00e9v"},{"key":"ref0038","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-019-0298-2"},{"key":"ref0039","author":"Arnedt","year":"2021","journal-title":"Insomnia in patients with a substance use disorder"},{"key":"ref0040","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2003.10400007"},{"key":"ref0041","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100034934"},{"key":"ref0042","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00592"}],"container-title":["African Journal of Primary Health Care &amp; Family Medicine"],"original-title":[],"link":[{"URL":"https:\/\/phcfm.org\/index.php\/phcfm\/article\/viewFile\/3386\/5661","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/phcfm.org\/index.php\/phcfm\/article\/viewFile\/3386\/5662","content-type":"application\/epub+zip","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/phcfm.org\/index.php\/phcfm\/article\/viewFile\/3386\/5663","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/phcfm.org\/index.php\/phcfm\/article\/viewFile\/3386\/5664","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/phcfm.org\/index.php\/phcfm\/article\/viewFile\/3386\/5664","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T10:16:57Z","timestamp":1664792217000},"score":1,"resource":{"primary":{"URL":"https:\/\/phcfm.org\/index.php\/phcfm\/article\/view\/3386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,11]]}},"URL":"https:\/\/doi.org\/10.4102\/phcfm.v14i1.3386","relation":{},"ISSN":["2071-2936","2071-2928"],"issn-type":[{"value":"2071-2936","type":"electronic"},{"value":"2071-2928","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,28]]}}}